Another MET-targeting antibody-drug conjugate (REGN5093-M114) is being studied in pre-clinical models and has shown promising anti-tumor activity in cells after progression following treatment with osimertinib and savolitinib [40]. This evidence concerns the gene MET and neoplasm.